PANTHERx® Rare Selected by Ionis as Specialty Pharmacy for TRYNGOLZA™ (olezarsen) [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
pleased to announce that it was selected by Ionis Pharmaceuticals, Inc. for the distribution of TRYNGOLZA™ (olezarsen), the first and only treatment approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). PANTHERx Rare is the nation's leading rare disease pharmacy. We exist for people living with rare and orphan diseases who deserve the best that medicine can offer. (PRNewsfoto/PANTHERx Rare) TRYNGOLZA is a GalNAc -conjugated antisense oligonucleotide therapy that selectively binds and degrades apoC-III mRNA to reduce hepatic production of apoC-III, a protein that regulates triglyceride metabolism. FCS is a rare, genetic disorder of fat metabolism characterized by extremely high plasma triglyceride levels. Most cases of FCS result from mutations in the LPL gene, leading to insufficient or impaired lipoprotein lipase (LPL) enzyme function. Lipoprotein lipase is responsible for br
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 30%? [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.MarketBeat
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood [Yahoo! Finance]Yahoo! Finance
- TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 11/6/24 - Beat
IONS
Sec Filings
- 12/26/24 - Form 4
- 12/20/24 - Form 8-K
- 11/14/24 - Form SC
- IONS's page on the SEC website